Bisphosphonates Reduce Fracture Risk in Prostate Cancer Patients
Researchers found that men with metastatic prostate cancer receiving androgen deprivation therapy (ADT) had a significantly lower risk of fractures when treated with a bisphosphonate alongside standard of care (SOC).
The study, published in the Annals of Oncology journal, suggests that bisphosphonates can be effective in reducing fracture risk in this patient population.
- The study was a large randomized trial.
- The training data set consisted of 1.2 million echocardiographic videos.
Men with metastatic prostate cancer receiving ADT had a significantly lower risk of fractures when treated with a bisphosphonate.
Author's summary: Bisphosphonates reduce fracture risk.